AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Research

Striving for the AIDS End Game: Translating Research Promise Into Public Health Success

Anthony Fauci

Dec. 1, 2013 marks the 25th annual commemoration of World AIDS Day. In highlighting this day, partners in the fight against HIV/AIDS will champion bold goals, such as “ending AIDS” and “getting to zero.” With the sober recognition that 35.3 million people are living with HIV/AIDS today, these goals may seem unattainable, perhaps even fanciful…

NIH Statement on World AIDS Day 2013

NIH logo

In the 25 years that have passed since the first annual commemoration of World AIDS Day, extraordinary scientific progress has been made in the fight against HIV/AIDS. That progress has turned an HIV diagnosis from an almost-certain death sentence to what is now for many, a manageable medical condition and nearly normal lifespan. We have…

Updated Pediatric HIV/AIDS Opportunistic Infection Prevention and Treatment Guidelines Released

AIDSinfo

The National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA), the Pediatric Infectious Disease Society (PIDS), and the American Academy of Pediatrics (AAP) announce the release of the updated Guidelines for the Prevention and Treatment of Opportunistic Infections…

Together on the Pathways to Wellness: Recovery and Efforts to Strengthen Viral Hepatitis Services

Ronald Valdiserri

Throughout September’s observance of National Recovery Month, individuals, organizations, and communities across the nation celebrated recovery from mental health issues and addiction challenges. Given the significant role that drug-using behaviors can play in the transmission of viral hepatitis, and the fact that alcohol intake often worsens liver disease among persons with chronic viral hepatitis, National Recovery…

FDA Safety Communication: Reducing the Risk of Hepatitis B Reactivation in Patients Using Two Immune-Suppressing and Anti-Cancer Drugs

FDA

On September 25, 2013, the Food and Drug Administration (FDA) issued a Drug Safety Communication announcing that the FDA has approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to add new Boxed Warning information about the risk of reactivation of hepatitis B virus (HBV) infection. The…

NIH Observes 20th Anniversary of Women’s Interagency HIV Study

NIAID

The largest and longest-running study to investigate the impact of HIV on women in the United States marks its 20th anniversary this month. Findings from the Women’s Interagency HIV Study (WIHS) have helped define how best to treat HIV-infected women in the United States and globally. The National Institute of Allergy and Infectious Diseases (NIAID),…

Webinar: PrEP Initiation and Adherence among Black Men who have Sex with Men (BMSM) in Three U.S. Cities

HIV Prevention Trails Network 073

Please join the HIV Prevention Trials Network (HPTN) launch of a Pre-Exposure Prophylaxis (PrEP) study for Black men who have sex with men (BMSM). The new study, HPTN 073, is a demonstration project designed to see if BMSM are willing to use Truvada® for PrEP. Date: Wed, Aug 14, 2013 Time: 2:00 PM EDT Duration: 1 hour 30 minutes…

FDA approves first rapid diagnostic test to detect both HIV-1 antigen and HIV-1/2 antibodies

FDA

The U.S. Food and Drug Administration today approved the first rapid Human Immunodeficiency Virus (HIV) test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma, and venous or fingerstick whole blood specimens. Approved for use as an aid in the diagnosis of HIV-1…